Implementing the EU in vitro diagnostic regulation – a European regulatory perspective on companion diagnostics-Reference-Cited by-同舟云学术

Implementing the EU in vitro diagnostic regulation – a European regulatory perspective on companion diagnostics

Published:2020-01-28 Issue:6 Volume:20 Page:565-567
ISSN:1473-7159
Container-title:Expert Review of Molecular Diagnostics
language:en
Short-container-title:Expert Review of Molecular Diagnostics

Author:

Ritzhaupt Armin¹^ORCID,Hayes Ivana¹,Ehmann Falk²

Affiliation:

1. Scientific and Regulatory Management Department, European Medicines Agency (EMA), Amsterdam, The Netherlands

2. Product Development Scientific Support Department, European Medicines Agency (EMA), Amsterdam, The Netherlands

Funder

funded

Publisher

Informa UK Limited

Subject

Genetics,Molecular Biology,Molecular Medicine,Pathology and Forensic Medicine

Link

https://www.tandfonline.com/doi/pdf/10.1080/14737159.2020.1720653

Reference23 articles.

1. Use of Chemotherapy plus a Monoclonal Antibody against HER2 for Metastatic Breast Cancer That Overexpresses HER2

2. The Development of the HercepTest

3. The drug diagnostic co-development concept paper

4. US FDA. Guidance for industry and food and drug administration staff. In Vitro Companion Diagnostic Devices. [cited 2019 Aug 28]. Available from: http://www.fda.gov/downloads/MedicalDevices/DeviceRegulationandGuidance/GuidanceDocuments/UCM262327.pdf

5. European Medicines Agency, Committee for Human Medicinal Products. Reflection paper on pharmacogenomics in oncology. 2008 April. [cited 2019 Aug 28]. Available from: https://www.ema.europa.eu/en/documents/scientific-guideline/reflection-paper-pharmacogenomics-oncology_en.pdf

Cited by 16 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Companion and complementary diagnostics as tools of precision medicine;Comprehensive Precision Medicine;2024

2. Current status of the analytical validation of next generation sequencing applications for pharmacogenetic profiling;Molecular Biology Reports;2023-10-03

3. A Systematic Database Approach to Identify Companion Diagnostic Testing in Clinical Trials under the New In Vitro Diagnostic Medical Devices Regulation;Diagnostics;2023-06-12

4. Biomarker‐Driven Developments in the Context of the New Regulatory Framework for Companion Diagnostics in the European Union;Clinical Pharmacology & Therapeutics;2023-05-25

5. Lymphocyte-activating gene 3 expression in tumor cells predicts immune checkpoint inhibitor response in triple negative breast cancer;Frontiers in Oncology;2023-03-16